From obesity to renal disease, chronic conditions remain some of the toughest challenges in veterinary medicine. Changemakers examine how next-generation therapeutics, supported by diagnostics and other modalities, can deliver sustainable results and change the way veterinarians manage long-term disease.
From generics to emerging technologies and distribution partnerships, innovative routes to market are expanding reach and reshaping the competitive landscape. Leaders share how new models are lowering barriers to entry, driving scale, accelerating time to market, and creating sustainable value across the ecosystem.
Panellists
Steve Shell
President
MWI Animal Health
Neeraj Agrawal
Managing Director
Felix Generics
Transboundary animal diseases (TADs) such as avian influenza, bluetongue virus, and foot-and-mouth disease pose serious risks to animal health, livestock production, and public health. Past outbreaks have exposed gaps in disease awareness and preparedness, with farmers often bearing the greatest impact. Effective prevention, through international collaboration, biosecurity, vaccination, and surveillance, requires coordinated action to stop the spread and support eradication efforts.
Moderator
Albert Picado
Principal Scientist Viral Diseases Research
Boehringer Ingelheim
Albert Picado is a Veterinary Epidemiologist with over 20 years of experience in designing and conducting epidemiological studies, as well as in the development, evaluation, and implementation of control tools for infectious diseases affecting both animals and humans. Currently serving as Principal Scientist within the Viral Diseases Research (VDR) team at Boehringer Ingelheim in Lyon (France), Albert provides strategic epidemiological support for the development of vaccines targeting priority infectious diseases. His work includes a strong focus on Transboundary Animal Diseases (TADs), contributing to global efforts to improve disease prevention and control through innovative vaccine solutions.
Our panellists will discuss where data and AI are going to have the greatest impact on advancing health outcomes, the delivery of care and R&D.
- AI’s impact on reducing the timeline between adoption of innovation in Human Health and Animal Health
- Improving capital efficiency - rethinking the R&D process with AI
- How common data structure and architecture design will facilitate industry collaboration and unleash the power of existing data
- Improving differential diagnosis at point of care – augmenting, not replacing, practitioner decision making
- Teaching future generations how to deliver care based on new and growing sources of data
Panellists
Paul Higgs
Chief Veterinary Officer
CVS Group Plc
Jackie Hunter
CEO
OI Pharma Partners Ltd
Tim Bettington
Executive Vice President, Corporate Strategy & Market Development
Elanco